Tag: Dr George D Yancopoulos

dupilumab

FDA Approves Dupixent® (dupilumab) for Moderate-to-severe Atopic Dermatitis in Adolescents

Therapy targets the IL-4/IL-13 pathway, a key driver of the allergic or type 2 inflammation that underlies atopic dermatitis.
AR101+dupilumab

Aimmune Therapeutics Announces Initiation of Phase 2 Study of AR101 With...

Trial Will Build on the Positive, Pivotal Phase 3 PALISADE Trial of AR101.
dupilumab

Study: Dupilumab Showed Positive Phase 3 Results in Adolescents with Inadequately...

"[dupilumab] blocks the IL-4/IL-13 pathway, which is emerging as a central driver of Type 2 allergic inflammation."

Connect with Us

36,531FansLike
94FollowersFollow
342FollowersFollow
2,523FollowersFollow
5,339FollowersFollow
37SubscribersSubscribe